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1. Introduction {#jia225222-sec-0005}
===============

Globally, the prevalence and incidence of hepatitis C virus (HCV) infection among people who inject drugs (PWID) is high, with approximately 42.4% to 62.1% of PWID estimated to be HCV antibody positive [1](#jia225222-bib-0001){ref-type="ref"}. The prevalence and incidence of HCV infection among human immunodeficiency virus (HIV)‐positive gay and bisexual men (GBM) is also considerable, with prevalence estimated to be between 5.3% and 7.3% [2](#jia225222-bib-0002){ref-type="ref"}, [3](#jia225222-bib-0003){ref-type="ref"}, [4](#jia225222-bib-0004){ref-type="ref"}, [5](#jia225222-bib-0005){ref-type="ref"}, [6](#jia225222-bib-0006){ref-type="ref"}, [7](#jia225222-bib-0007){ref-type="ref"}. While variations exist in the incidence and prevalence of HCV infection among HIV‐positive GBM across geographical regions, transmission of HCV has been sustained among this population in recent years [8](#jia225222-bib-0008){ref-type="ref"}, [9](#jia225222-bib-0009){ref-type="ref"}. Ongoing and overlapping transmission of HCV among these groups highlights the need for further investigation of factors that influence transmission of this virus [10](#jia225222-bib-0010){ref-type="ref"}, [11](#jia225222-bib-0011){ref-type="ref"}. While it is hypothesized that treatment as prevention strategies using direct‐acting antiviral (DAA) therapies may contribute to HCV elimination [12](#jia225222-bib-0012){ref-type="ref"}, [13](#jia225222-bib-0013){ref-type="ref"}, [14](#jia225222-bib-0014){ref-type="ref"}, [15](#jia225222-bib-0015){ref-type="ref"}, [16](#jia225222-bib-0016){ref-type="ref"}, [17](#jia225222-bib-0017){ref-type="ref"}, [18](#jia225222-bib-0018){ref-type="ref"}, more detailed characterization of the transmission of HCV is needed to guide the implementation of these strategies [19](#jia225222-bib-0019){ref-type="ref"}, [20](#jia225222-bib-0020){ref-type="ref"}.

Beginning in the late 1990s, the incidence of HCV co‐infection in HIV‐positive GBM began to increase in high‐income countries [3](#jia225222-bib-0003){ref-type="ref"}, [21](#jia225222-bib-0021){ref-type="ref"}, such as Switzerland [22](#jia225222-bib-0022){ref-type="ref"} and the United Kingdom [23](#jia225222-bib-0023){ref-type="ref"}. The incidence of HCV infection in these populations remains high to the present time [9](#jia225222-bib-0009){ref-type="ref"}. The findings were mirrored in Australia, with specific transmission networks identified among HIV‐positive GBM [5](#jia225222-bib-0005){ref-type="ref"}, [24](#jia225222-bib-0024){ref-type="ref"}. A model including both sexual and drug use risk behaviour [25](#jia225222-bib-0025){ref-type="ref"}, [26](#jia225222-bib-0026){ref-type="ref"}, [27](#jia225222-bib-0027){ref-type="ref"} was proposed to explain HCV transmission among HIV‐positive GBM, highlighting the complex nature of transmission. Phylogenetic studies of recent HCV infection found that HIV co‐infection and HCV genotype 1a were associated with transmission clusters [28](#jia225222-bib-0028){ref-type="ref"}, [29](#jia225222-bib-0029){ref-type="ref"}.

Phylogenetic analyses can uncover patterns of disease transmission [30](#jia225222-bib-0030){ref-type="ref"}, [31](#jia225222-bib-0031){ref-type="ref"}, rather than just patterns of disease acquisition, such as in traditional epidemiological studies. While phylogenetic techniques cannot determine the exact direction of transmission, sources and trends can be identified on a population level [32](#jia225222-bib-0032){ref-type="ref"}, [33](#jia225222-bib-0033){ref-type="ref"}. By combining data from these analyses with detailed behavioural, clinical and demographic data, underlying networks can be detected, that may otherwise remain hidden [34](#jia225222-bib-0034){ref-type="ref"}, [35](#jia225222-bib-0035){ref-type="ref"}.

Latent class analysis (LCA) has been used to characterize patterns of polydrug use and other types of multi‐risk profiles in relation to HIV and HCV acquisition [36](#jia225222-bib-0036){ref-type="ref"}, [37](#jia225222-bib-0037){ref-type="ref"}, [38](#jia225222-bib-0038){ref-type="ref"}. However, it has only recently been combined with phylogenetic data to understand transmission risk for HIV and HCV [39](#jia225222-bib-0039){ref-type="ref"}, [40](#jia225222-bib-0040){ref-type="ref"}. LCA assumes the population consists of sub‐populations (latent classes) that differ in their distributions of included variables and provides the ability to identify these latent classes. The ability to stratify analyses based on HIV infection status with increased study size, and insights provided by LCA, combined with phylogenetic analysis, delivers a unique opportunity to better understand transmission of HCV among different groups. These insights could identify potential targets for the optimal implementation of treatment as prevention and provide a foundation for the future evaluation of the effectiveness of treatment as prevention.

The aim of this study was to identify multi‐risk profiles and factors associated with phylogenetic clustering of recent HCV infection in Australia and New Zealand between 2004 and 2015 among people with and without HIV infection.

2. Methods {#jia225222-sec-0006}
==========

2.1. Study population and design {#jia225222-sec-0007}
--------------------------------

Data and specimens from five studies of recent HCV (duration of infection \<18 months) in Australia and New Zealand were used for this study: ATAHC [5](#jia225222-bib-0005){ref-type="ref"}, RAMPT‐C [41](#jia225222-bib-0041){ref-type="ref"}, ATAHC II/DARE‐C I [42](#jia225222-bib-0042){ref-type="ref"} and DARE‐C II [43](#jia225222-bib-0043){ref-type="ref"}. Participants were recruited through a network of tertiary clinics and hospitals between 2004 and 2015 (published elsewhere [5](#jia225222-bib-0005){ref-type="ref"}, [41](#jia225222-bib-0041){ref-type="ref"}, [42](#jia225222-bib-0042){ref-type="ref"}, [43](#jia225222-bib-0043){ref-type="ref"} and described in Data [S1](#jia225222-sup-0001){ref-type="supplementary-material"}). For inclusion in this study, participants had to have recent HCV defined as initial detection of serum anti‐HCV antibody and/or HCV RNA within six months of enrolment and either (i) documented recent HCV seroconversion (anti‐HCV antibody negative result in the 18 (DARE‐C II) or 24 (ATAHC, ATAHC II, DARE‐C I, RAMPT‐C) months prior to enrolment) or (ii) acute clinical hepatitis (jaundice or alanine aminotransferase (ALT) greater than 10 times the upper limit of normal (ULN)) within the previous 12 months with exclusion of other causes of acute hepatitis, and estimated duration of HCV infection \<12 (DARE‐C II) or 18 (ATAHC, ATAHC II, DARE‐C I, RAMPT‐C) months at screening. Calculation of the estimated date of infection for subjects is described in Data [S1](#jia225222-sup-0001){ref-type="supplementary-material"}. The first available HCV RNA‐positive Ethylenediaminetetraacetic acid or acid‐citrate‐dextrose plasma sample following detection of HCV was selected. All participants provided a written informed consent and protocols were approved by appropriate Human Research Ethics Committees.

2.2. HCV RNA sequencing and phylogenetic analysis {#jia225222-sec-0008}
-------------------------------------------------

HCV RNA was extracted, Core‐E2 region amplified (nucleotides 347 to 1750 in H77 reference sequence (GenBank accession no. [NC_004102](NC_004102))), then Sanger sequenced (method published elsewhere [44](#jia225222-bib-0044){ref-type="ref"} and described in Data [S1](#jia225222-sup-0001){ref-type="supplementary-material"}). The fragment analysed was 1104 bp long following removal of hypervariable region one (HVR1) to improve cluster resolution [44](#jia225222-bib-0044){ref-type="ref"}. Sequences were aligned using ClustalW [45](#jia225222-bib-0045){ref-type="ref"} with reference sequences from the Los Alamos National Laboratory HCV database [46](#jia225222-bib-0046){ref-type="ref"} and unrelated sequences from overseas [47](#jia225222-bib-0047){ref-type="ref"}, [48](#jia225222-bib-0048){ref-type="ref"} to disrupt spurious clustering and support identification of locally expanding of clusters [49](#jia225222-bib-0049){ref-type="ref"}. Maximum likelihood phylogenetic trees were inferred for genotypes 1, 3 and 2/4/6 combined in RAxML [50](#jia225222-bib-0050){ref-type="ref"} through CIPRES Science Gateway [51](#jia225222-bib-0051){ref-type="ref"} under the general time reversible model of nucleotide substitution with substitution rate heterogeneity and 1000 bootstrap replicates. JModelTest [52](#jia225222-bib-0052){ref-type="ref"}, [53](#jia225222-bib-0053){ref-type="ref"} was used to determine the nucleotide substitution model. Clusters and pairs were identified using ClusterPicker [54](#jia225222-bib-0054){ref-type="ref"} with 90% bootstrap support threshold and 5% mean maximum genetic distance cutoff. Sensitivity analyses, performed by varying genetic distance threshold between 1.5% and 5% with and without 90% bootstrap threshold, and previous studies [28](#jia225222-bib-0028){ref-type="ref"}, [44](#jia225222-bib-0044){ref-type="ref"}, determined 5% mean maximum genetic distance was the most epidemiologically relevant cutoff to define clustering for this population.

2.3. Study outcomes {#jia225222-sec-0009}
-------------------

The primary study outcome was phylogenetic clustering of HCV infections, as defined by two or more participants with HCV genome sequence within the bootstrap and genetic distance threshold cutoff. A pair was defined as two participants within the cutoff and a cluster was defined as three or more participants within the cutoff.

2.4. Latent class analysis {#jia225222-sec-0010}
--------------------------

LCA was used to identify groups of participants sharing behavioural and epidemiological characteristics, to identify multi‐risk profiles associated with phylogenetic clustering [39](#jia225222-bib-0039){ref-type="ref"}. LCA models were built using only risk behaviour and basic demographic variables to enhance real‐world applicability of resulting multi‐risk profiles. The LCA model included all available variables indicating risk behaviours related to HCV transmission; mode of HCV acquisition (sexual acquisition or injecting drug use (IDU) acquisition, defined by clinician), IDU (never injected, injected but not within the last six months or injected within the last six months and the last drug that was injected) [55](#jia225222-bib-0055){ref-type="ref"}, [56](#jia225222-bib-0056){ref-type="ref"}, [57](#jia225222-bib-0057){ref-type="ref"}, [58](#jia225222-bib-0058){ref-type="ref"}, sex and older age (in categories: \<45, \>45 years). Multiple models were estimated with varying numbers of classes (from one to eight classes) and no covariate in SAS (version 9.4: Sas Institute Inc., Cary, NC, USA), using the PROC LCA plugin [59](#jia225222-bib-0059){ref-type="ref"}, [60](#jia225222-bib-0060){ref-type="ref"}. Bayesian information criterion (BIC), Akaike information criterion (AIC), adjusted BIC (aBIC) and adjusted AIC (aAIC) were used to determine the best‐fitting model, in addition to entropy and epidemiological meaningfulness of class structure. The best‐fitting model was run with distal outcome (phylogenetic clustering) and each participant had posterior probability of belonging to each latent class of the fitted model calculated. For subsequent analysis [39](#jia225222-bib-0039){ref-type="ref"}, [61](#jia225222-bib-0061){ref-type="ref"}, participants were allocated to the latent class for which they had the highest posterior membership probability, with class treated as an observed variable in adjusted logistic regression analysis.

2.5. Statistical analyses {#jia225222-sec-0011}
-------------------------

Multivariate logistic regression analysis was used to identify multi‐risk profiles and factors associated with being in a pair or cluster. Factors hypothesized to be associated with being in a pair or cluster that were assessed included: older age [5](#jia225222-bib-0005){ref-type="ref"}, [62](#jia225222-bib-0062){ref-type="ref"}, [63](#jia225222-bib-0063){ref-type="ref"}, male sex (vs. female sex) [64](#jia225222-bib-0064){ref-type="ref"}, HIV infection or sexual acquisition of HCV [5](#jia225222-bib-0005){ref-type="ref"}, [6](#jia225222-bib-0006){ref-type="ref"}, [7](#jia225222-bib-0007){ref-type="ref"}, [65](#jia225222-bib-0065){ref-type="ref"} and recent injection drug use (defined as injecting anytime in the last six months prior to screening) [12](#jia225222-bib-0012){ref-type="ref"}, [66](#jia225222-bib-0066){ref-type="ref"}, [67](#jia225222-bib-0067){ref-type="ref"}. Due to collinearity between HCV/HIV co‐infection and sexual acquisition of HCV (all persons with clinician assigned sexual acquisition were HCV/HIV co‐infected), models were constructed adjusting for these factors separately. Analyses were also stratified by HIV infection status, and to account for potential unmeasured confounding introduced by cohort characteristics, adjusted logistic regression analysis was performed using mixed modelling, with a random intercept for cohort. For all analyses, statistically significant differences were assessed at *p *\< 0.05; *p*‐values are two‐sided. All analyses were performed using STATA software (version 14; StataCorp L.P., College Station, TX, USA).

3. Results {#jia225222-sec-0012}
==========

3.1. Study population {#jia225222-sec-0013}
---------------------

In total, 296 subjects were eligible for inclusion in this study (Figure [1](#jia225222-fig-0001){ref-type="fig"}), with 237 HCV Core‐E2 sequences obtained. The characteristics of participants with a Core‐E2 sequence are shown in Table [1](#jia225222-tbl-0001){ref-type="table"}. The median age was 37 (interquartile range 29 to 46) years, 79% were male, 84% were White people and 52% were HIV positive. Homosexual exposure was universally reported as a risk factor for HIV acquisition among those with HCV/HIV co‐infection (n = 123).

![Flow chart of sources of participants and sequences from five studies of recent hepatitis C virus (HCV) infection in Australia between 2004 and 2015\
ATAHC, Australian Trial in Acute Hepatitis C; RAMPT‐C, Defining risk and mechanisms of permucosal transmission for acute HCV infection within high‐risk populations; ATAHC II, Australian Trial in Acute Hepatitis C II; DARE‐C I, DAA‐based therapy for recently acquired hepatitis C I; DARE‐C II, DAA‐based therapy for recently acquired hepatitis C II; E2, envelope 2; G, genotype.](JIA2-22-e25222-g001){#jia225222-fig-0001}

###### 

Characteristics of participants with an available hepatitis C virus (HCV) Core‐E2 sequence from five studies of recent HCV infection in Australia and New Zealand recruited between 2004 and 2015

  Characteristic                                                                                           Overall         ATAHC I                                    RAMPT‐C                                    ATAHC II                                   DARE‐C I                                   DARE‐C II
  -------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------
  Period of study recruitment/follow‐up                                                                                    2004 to 2007                               2009 to 2013                               2011 to 2013                               2013 to 2015                               2014 to 2015
  Total n (%)                                                                                              (n = 237)       (n = 119)                                  (n = 25)                                   (n = 60)                                   (n = 15)                                   (n = 18)
  Age (median years, Q2 to Q3)                                                                             38 (29 to 46)   33 (25 to 41)                              45 (37 to 50)                              41 (32 to 47)                              46 (44 to 53)                              44 (31 to 50)
  Gender                                                                                                                                                                                                                                                                                               
  Female                                                                                                   37 (16%)        28 (24%)                                   [a](#jia225222-note-0004){ref-type="fn"}   8 (13%)                                    0 (0%)                                     1 (6%)
  Male                                                                                                     187 (79%)       81 (68%)                                   25 (100%)                                  52 (87%)                                   13 (87%)                                   16 (89%)
  Other[b](#jia225222-note-0004){ref-type="fn"}                                                            13 (5%)         10 (8%)                                    0 (0%)                                     0 (0%)                                     2 (13%)                                    1 (6%)
  City                                                                                                                                                                                                                                                                                                 
  Sydney                                                                                                   109 (46%)       46 (39%)                                   14 (56%)                                   28 (47%)                                   13 (87%)                                   8 (44%)
  Melbourne                                                                                                88 (37%)        50 (42%)                                   11 (44%)                                   22 (37%)                                   0 (0%)                                     5 (28%)
  Adelaide                                                                                                 27 (11%)        15 (13%)                                   [a](#jia225222-note-0004){ref-type="fn"}   10 (17%)                                   2 (11%)                                    [a](#jia225222-note-0004){ref-type="fn"}
  Other[c](#jia225222-note-0004){ref-type="fn"}                                                            13 (6%)         8 (7%)                                     [a](#jia225222-note-0004){ref-type="fn"}   [a](#jia225222-note-0004){ref-type="fn"}   [a](#jia225222-note-0004){ref-type="fn"}   5 (28%)
  HIV infection                                                                                                                                                                                                                                                                                        
  Positive                                                                                                 123 (52%)       36 (30%)                                   24 (96%)                                   38 (63%)                                   11 (73%)                                   14 (78%)
  Negative                                                                                                 114 (48%)       83 (70%)                                   1 (4%)                                     22 (37%)                                   4 (27%)                                    4 (22%)
  Acquisition of HCV[d](#jia225222-note-0004){ref-type="fn"}                                                                                                                                                                                                                                           
  Sexual                                                                                                   97 (41%)        36 (30%)                                   18 (72%)                                   26 (43%)                                   9 (60%)                                    8 (44%)
  Injecting drug use                                                                                       121 (51%)       68 (57%)                                   7 (28%)                                    33 (55%)                                   4 (27%)                                    9 (50%)
  Unknown                                                                                                  19 (8%)         15 (13%)                                   0 (0%)                                     1 (2%)                                     2 (13%)                                    1 (6%)
  Estimated year of HCV acquisition                                                                                                                                                                                                                                                                    
  2003 to 2005                                                                                             72 (30%)        72 (%)                                     [a](#jia225222-note-0004){ref-type="fn"}   [a](#jia225222-note-0004){ref-type="fn"}   [a](#jia225222-note-0004){ref-type="fn"}   [a](#jia225222-note-0004){ref-type="fn"}
  2006 to 2008                                                                                             48 (20%)        47 (%)                                     1 (4%)                                     [a](#jia225222-note-0004){ref-type="fn"}   [a](#jia225222-note-0004){ref-type="fn"}   [a](#jia225222-note-0004){ref-type="fn"}
  2009 to 2011                                                                                             43 (19%)        [a](#jia225222-note-0004){ref-type="fn"}   22 (88%)                                   20 (33%)                                   1 (7%)                                     [a](#jia225222-note-0004){ref-type="fn"}
  2012 to 2014                                                                                             74 (31%)        [a](#jia225222-note-0004){ref-type="fn"}   2 (8%)                                     40 (67%)                                   14 (93%)                                   18 (100%)
  HCV genotype                                                                                                                                                                                                                                                                                         
  1a                                                                                                       131 (55%)       59 (50%)                                   17 (68%)                                   30 (50%)                                   14 (93%)                                   11 (61%)
  1b                                                                                                       10 (4%)         8 (7%)                                     0 (0%)                                     1 (2%)                                     1 (7%)                                     0 (0%)
  3a                                                                                                       89 (38%)        48 (40%)                                   7 (28%)                                    28 (46%)                                   0 (0%)                                     6 (33%)
  2/4/6                                                                                                    7 (3%)          3 (3%)                                     1 (4%)                                     1 (2%)                                     0 (0%)                                     1 (6%)
  Injection drug use                                                                                                                                                                                                                                                                                   
  Never injected                                                                                           57 (24%)        18 (15%)                                   14 (56%)                                   15 (25%)                                   7 (47%)                                    3 (16%)
  Injected ever, but not recently[e](#jia225222-note-0004){ref-type="fn"}                                  78 (33%)        52 (44%)                                   5 (20%)                                    10 (17%)                                   2 (13%)                                    9 (50%)
  Injected recently[e](#jia225222-note-0004){ref-type="fn"}                                                89 (37%)        42 (35%)                                   6 (24%)                                    34 (56%)                                   2 (13%)                                    5 (28%)
  Unknown                                                                                                  13 (5%)         7 (6%)                                     0 (0%)                                     1 (2%)                                     4 (27%)                                    1 (6%)
  Drug recently[e](#jia225222-note-0004){ref-type="fn"} injected[f](#jia225222-note-0004){ref-type="fn"}                                                                                                                                                                                               
  Heroin                                                                                                   16 (18%)        14 (33%)                                   0 (0%)                                     2 (6%)                                     0 (0%)                                     0 (0%)
  Methadone/buprenorphine                                                                                  18 (20%)        18 (43%)                                   0 (0%)                                     0 (0%)                                     0 (0%)                                     0 (0%)
  Other opioids                                                                                            7 (8%)          5 (12%)                                    0 (0%)                                     1 (3%)                                     1 (50%)                                    0 (0%)
  Methamphetamine/amphetamine                                                                              30 (34%)        0 (0%)                                     6 (100%)                                   18 (53%)                                   1(50%)                                     5 (100%)
  Unknown                                                                                                  18 (20%)        5 (12%)                                    0 (0%)                                     13 (38%)                                   0 (0%)                                     0 (0%)
  Opioid substitution therapy ever                                                                         25 (11%)        16 (13%)                                   0 (0%)                                     8 (13%)                                    1 (7%)                                     0 (0%)

Percentages indicate column percentages, except for drug last injected[f](#jia225222-note-0004){ref-type="fn"}.

ATAHC, Australian Trial in Acute Hepatitis C; RAMPT‐C, Defining risk and mechanisms of permucosal transmission for acute HCV infection within high‐risk populations; ATAHC II, Australian Trial in Acute Hepatitis C II; DARE‐C I, DAA‐based therapy for recently acquired hepatitis C I; DARE‐C II, DAA‐based therapy for recently acquired hepatitis C II; Q, quartiles; NA, variable not available for study.

^a^Variable not applicable to study; ^b^other includes one transgender subject and 12 subjects for which variable was unavailable; ^c^Newcastle, Brisbane, Auckland or Perth; ^d^acquisition was determined by the clinician according to reported risk factors; ^e^within last six months prior to sample date; ^f^among people who reported recent injecting (within last six months prior to sample date).

John Wiley & Sons, Ltd

3.2. Phylogenetic pair and cluster composition {#jia225222-sec-0014}
----------------------------------------------

Phylogenetic trees were constructed separately for genotypes 1, 3 and G2/4/6 combined (Figure [S1](#jia225222-sup-0001){ref-type="supplementary-material"}). Overall, 46% of participants were in a pair or cluster, with 60% (74/123) of HCV/HIV co‐infected participants in a pair or cluster compared to 30% (34/114) of HCV mono‐infected participants (*p *\< 0.001). Clusters ranged in size from three to eight participants, shown in Figure [2](#jia225222-fig-0002){ref-type="fig"}. Many clusters displayed homogeneous characteristics, such as clusters containing exclusively HCV/HIV co‐infected individuals (Clusters 1 to 4, 8, 9, 29, Figure [2](#jia225222-fig-0002){ref-type="fig"}), individuals with sexual acquisition of HCV infection (Clusters 2 and 31, Figure [2](#jia225222-fig-0002){ref-type="fig"}) or IDU acquisition (Cluster 6, Figure [2](#jia225222-fig-0002){ref-type="fig"}), individuals with history of IDU (Clusters 2 and 6, Figure [2](#jia225222-fig-0002){ref-type="fig"}) or individuals from one city (Clusters 1, 3, 6, 7, 9, 29 to 31, Figure [2](#jia225222-fig-0002){ref-type="fig"}). Some clusters displayed heterogeneous characteristics, such as mixing of age categories, route of acquisition of HCV and IDU history.

![Clusters from maximum likelihood phylogenetic trees, constructed with sequences from Core‐E2 region of hepatitis C virus (HCV) obtained from people with recent infection in Australia between 2004 and 2015 (full trees in Figure [S1](#jia225222-sup-0001){ref-type="supplementary-material"})\
All identified clusters at \<5% mean maximum genetic distance cutoff are displayed (genotype 1a numbered \#1 to 9 and genotype 3a numbered \#28 to 31). Scale bars indicate nucleotide substitutions per site. Tip names are coloured by latent class analysis (LCA) highest posterior probability classes (Class 1: PWID; Class 2: HIV‐positive GBSM or Class 3: GBSM with injecting drug use (IDU)). Numbers at tips represent estimated year of infection for each participant (if available) and letters represent the city where participants were recruited. Squares represent males, circles females, filled circles or squares represent a participant with HCV/HIV co‐infection, empty circles or squares represent HCV mono‐infection, and light green represents participants who are over 45 years of age, with blue representing under 45 years of age. Small diamonds represent participants who acquired HCV infection sexually, with pentagons representing IDU acquisition. A triangle represents participants never reporting IDU, an empty star represents reporting IDU ever but not recently and a filled star represents reporting recent IDU.](JIA2-22-e25222-g002){#jia225222-fig-0002}

3.3. Factors associated with membership in a pair or cluster overall {#jia225222-sec-0015}
--------------------------------------------------------------------

In a logistic regression model adjusting for age, gender and city, only HIV infection remained associated with membership in a pair/cluster (vs. HCV mono‐infection; adjusted odds ratio (AOR), 2.30; 95% confidence interval (CI), 1.07, 4.94) (Table [S1](#jia225222-sup-0001){ref-type="supplementary-material"}). In a logistic regression model adjusting for age, gender, city and mode of HCV acquisition, only HCV genotype 3a infection (vs. genotype 1a; AOR, 2.09, 95% CI, 1.11, 3.95) and infection with an HCV genotype other than 1a or 3a (vs. genotype 1a; AOR, 3.98, 95% CI, 1.21, 13.02) remained associated with being in a pair/cluster (Table [S1](#jia225222-sup-0001){ref-type="supplementary-material"}).

3.4. Factors associated with membership of a pair or cluster, stratified by HIV infection status {#jia225222-sec-0016}
------------------------------------------------------------------------------------------------

In logistic regression analysis stratified by HIV infection status, among HCV mono‐infected participants, only HCV genotype 3a (vs. genotype 1a; AOR, 4.35, 95% CI, 1.42, 13.30) was associated with being in a pair/cluster (Table [S2](#jia225222-sup-0001){ref-type="supplementary-material"}). Among HCV/HIV co‐infected participants, no factors were significant (Table [S3](#jia225222-sup-0001){ref-type="supplementary-material"}).

3.5. Multi‐risk profiles {#jia225222-sec-0017}
------------------------

After comparison of fit statistics, a model with three classes was found to be best fit (Table [S4](#jia225222-sup-0001){ref-type="supplementary-material"}). Based on item response probabilities for observed classes, multi‐risk profiles were named according to relative distributions of participant characteristics (Table [2](#jia225222-tbl-0002){ref-type="table"}). Class 1 was named "PWID," as class probability for having recently injected drugs or acquiring HCV through IDU were highest for this class, and no participants assigned to this class had HIV infection. Class 2 was named "HIV‐positive GBM with low probability of IDU," as class probability for being male was almost 1, probability of acquiring HCV sexually was almost 1, probability of having never injected drugs was highest in this class, and almost all participants assigned to this class had HIV co‐ infection. Class 3 was named "GBM with IDU & sexual risk behaviour," as class probability for being male was almost 1, probability of recently injecting methamphetamine was highest, and the majority of participants had HIV co‐ infection. Almost all clusters contained mostly participants assigned to Class 2, with small numbers of participants assigned to Class 3 distributed among these clusters. Only three clusters contained participants assigned to Class 1, with this class having the lowest likelihood of being in a cluster.

###### 

Response probability for characteristics of the three multi‐risk profiles identified by Latent Class Analysis among five studies of recent hepatitis C virus (HCV) infection in Australia and New Zealand recruited between 2004 and 2015

  Characteristic                                                                       Class response probability            
  ------------------------------------------------------------------------------------ ---------------------------- -------- --------
  Probability of class membership                                                      0.31                         0.39     0.30
  Aged over 45 years                                                                   \<0.01                       0.52     0.33
  Male                                                                                 0.53                         0.96     0.98
  Acquisition of HCV[b](#jia225222-note-0006){ref-type="fn"}                                                                 
  IDU                                                                                  \>0.99                       \<0.01   0.79
  Sexual                                                                               \<0.01                       \>0.99   0.21
  IDU history                                                                                                                
  Most recently^\^^ injected heroin                                                    0.31                         0.01     \<0.01
  Most recently^\^^ injected methamphetamine[a](#jia225222-note-0006){ref-type="fn"}   0.29                         0.11     0.52
  Have injected ever, but not recently                                                 0.38                         0.25     0.48
  Never injected                                                                       0.02                         0.63     \<0.01
  HIV positive[c](#jia225222-note-0006){ref-type="fn"}                                 \<0.01                       0.96     0.60

HCV, hepatitis C virus; PWID, people who inject drugs; GBM, gay and bisexual men; IDU, injecting drug use; HIV, human immunodeficiency virus.

\^recent defined as within last 6 months; ^a^Methamphetamine or amphetamine; ^b^acquisition was determined by the clinician according to reported risk factors; ^c^HIV co‐infection was not included in model used to build latent classes due to collinearity with sexual acquisition of HCV. However, proportion of people with HIV co‐infection in each class was estimated here by assigning individuals to the class with highest posterior membership probability.
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3.6. Multi‐risk profiles associated with being in a pair or cluster {#jia225222-sec-0018}
-------------------------------------------------------------------

In unadjusted logistic regression analysis, both Class 2 "HIV‐positive GBM with low probability of IDU'' and Class 3 "GBM with IDU & sexual risk behaviour" (vs. Class 1 PWID) were associated with membership in a pair/cluster (Table [3](#jia225222-tbl-0003){ref-type="table"}). In adjusted analysis, membership in a pair/cluster was associated with Class 2 (vs. Class 1; AOR, 3.40, 95% CI, 1.52, 7.60), HCV genotype 3a infection (vs. genotype 1a; AOR, 1.94, 95% CI, 1.06, 3.57) and infection with a non 1a/3a HCV genotype (vs. genotype 1a; AOR, 4.26, 95% CI, 1.31, 13.84).

###### 

Multivariate logistic regression of factors associated with phylogenetic clustering, including multi‐risk profiles, among hepatitis C virus (HCV) Core‐E2 sequences (at 5% genetic distance threshold) among participants from five studies of recent HCV infection in Australia and New Zealand recruited between 2004 and 2015

  Characteristic                                               Overall     Unclustered   Clustered   Membership in cluster n ≥ 2                                                                                                 
  ------------------------------------------------------------ ----------- ------------- ----------- ----------------------------- ------------- --------- ---------- ----------------- ----------- ---------- ----------------- -----------
  City                                                                                                                                                                                                                           
  Other[a](#jia225222-note-0009){ref-type="fn"}                40 (17%)    28 (21%)      12 (11%)    Ref                           --            --        Ref        --                --          Ref        --                --
  Sydney                                                       109 (46%)   57 (44%)      52 (48%)    2.13                          0.98, 4.61    0.056     1.15       0.47, 2.81        0.753       1.41       0.60, 3.29        0.433
  Melbourne                                                    88 (37%)    44 (34%)      44 (41%)    2.33                          1.05, 5.17    0.037     1.71       0.73, 4.02        0.217       2.18       0.93, 5.09        0.072
  HIV infection                                                                                                                                                                                                                  
  Negative                                                     114 (48%)   80 (62%)      34 (31%)    Ref                           --            --        Ref        --                --          NI         NI                NI
  Positive                                                     123 (52%)   49 (38%)      74 (69%)    3.55                          2.07, 6.09    \<0.001   **2.73**   **1.45, 5.15**    **0.002**   NI         NI                NI
  HCV genotype                                                                                                                                                                                                                   
  1a                                                           131 (55%)   86 (67%)      45 (42%)    Ref                           --            --        Ref        --                --          Ref        --                --
  3a                                                           89 (38%)    38 (29%)      51 (47%)    2.56                          1.47, 4.46    0.001     1.83       0.99, 3.37        0.052       **1.94**   **1.06, 3.57**    **0.032**
  Other                                                        17 (7%)     5 (4%)        12 (11%)    4.59                          1.52, 13.83   0.007     **3.28**   **1.02, 10.54**   **0.046**   **4.26**   **1.31, 13.84**   **0.016**
  Multi‐risk profile[b](#jia225222-note-0009){ref-type="fn"}                                                                                                                                                                     
  Class 1 PWID                                                 59 (25%)    45 (34%)      14 (13%)    Ref                           --            --        NI         NI                NI          Ref        --                --
  Class 2 HIV‐positive GBM with low probability of IDU         97 (41%)    42 (33%)      55 (51%)    4.21                          2.05, 8.66    \<0.001   NI         NI                NI          **3.40**   **1.52, 7.60**    **0.003**
  Class 3 GBM with IDU & sexual risk behaviour                 81 (34%)    42 (33%)      39 (36%)    2.98                          1.42, 6.26    0.004     NI         NI                NI          2.22       0.96, 5.15        0.062

Percentages indicate column percentages. Factors remaining significant in adjusted analyses (*p* \< 0.05) are highlighted in bold.

HIV, human immunodeficiency virus; HCV, hepatitis C virus; PWID, people who inject drugs; GBM, gay and bisexual men; IDU, injecting drug use, CI, confidence interval; NI, not included; Ref, reference.

^a^Adelaide, Newcastle, Auckland, Brisbane or Perth; ^b^multi‐risk profile assigned corresponds to the profile with the highest posterior probability for that individual.
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4. Discussion {#jia225222-sec-0019}
=============

This study characterizes associations between overlapping and co‐occurring risk factors and HCV phylogenetic clustering among participants from five studies of recent HCV infection in Australia and New Zealand between 2004 and 2015. HIV/HCV co‐infection, recruitment in Melbourne and HCV genotype 3a infection were independently associated with being in a pair or cluster. LCA identified three multi‐risk profiles that included: (1) "PWID", (2) "HIV‐positive GBM with low probability of IDU" and (3) "GBM with IDU & sexual risk behaviour." Phylogenetic clustering was independently associated with membership in risk profile (2) "HIV‐positive GBM with low probability of IDU" after adjusting for other factors. These findings suggest that there are different sub‐populations at risk of HCV transmission even within those identifying as having a sexual or drug use risk. Thus, although both risk groups 2 and 3 had potential for sexual transmission, networks were able to be potentially identified based on combinations of risk factors. Different strategies may be warranted to address transmission within different networks. These findings identify a combination of participant characteristics that may be associated with HCV transmission or acquisition, providing potential targets for the implementation of public health interventions. This study describes a robust methodology for understanding populations at greater risk of viral transmission where risk factors overlap or co‐occur.

The association between HCV subtype 3a and phylogenetic clustering, with all clusters containing individuals infected over multiple years, is consistent with other reports of an increased proportion of incident HCV infection as a result of subtype 3a, compared to 1a, particularly among HIV‐negative PWID [68](#jia225222-bib-0068){ref-type="ref"}, a smaller population of infected people, and more recent introduction of subtype 3a to Australia, compared to 1a [69](#jia225222-bib-0069){ref-type="ref"}. This phenomenon has also been observed in countries such as Scotland [70](#jia225222-bib-0070){ref-type="ref"}, Germany [71](#jia225222-bib-0071){ref-type="ref"}, [72](#jia225222-bib-0072){ref-type="ref"}, England [73](#jia225222-bib-0073){ref-type="ref"}, Canada and the United States [69](#jia225222-bib-0069){ref-type="ref"}. This contrasts with a previous analysis which found an association between HCV subtype 1a and phylogenetic clustering [28](#jia225222-bib-0028){ref-type="ref"}, which may be explained by the more recent period of recruitment and higher proportion of participants with HCV/HIV co‐infection sampled in this study. This observed recent increase in transmission of subtype 3a supports broad availability and uptake of potent pan‐genotypic DAA regimens.

This study found that HCV/HIV co‐infection was independently associated with phylogenetic clustering. HIV infection was acquired exclusively homosexually among participants with HCV/HIV co‐infection in this study; however, many participants with HCV/HIV co‐infection reported both sexual and drug risk factors for HCV acquisition. While evidence has emerged that supports sexual transmission of HCV among GBM, both with and without HIV co‐infection [41](#jia225222-bib-0041){ref-type="ref"}, [74](#jia225222-bib-0074){ref-type="ref"}, [75](#jia225222-bib-0075){ref-type="ref"}, the presence of co‐occurring and overlapping risk factors among participants may conceal the contribution that sexual networks have on HCV transmission. While sexual acquisition of HCV infection was not associated with phylogenetic clustering, membership in the multi‐risk profile Class (2) "HIV‐positive GBM with low probability of IDU" was independently associated with phylogenetic clustering. This multi‐risk profile consisted of males who exclusively had HCV/HIV co‐infection, acquired HCV infection sexually and reported very little IDU, either recently or ever. This pattern was also evident in clusters observed that contained HIV‐positive men with no history of IDU and reported sexual acquisition of HCV (e.g. Clusters 3 and 31, Figure [2](#jia225222-fig-0002){ref-type="fig"}). This supports previous findings suggesting the sexual networks among HIV‐positive GBM through which HCV is transmitted are highly connected in Australia [24](#jia225222-bib-0024){ref-type="ref"}, and have potentially been densely sampled in this study, particularly compared to injecting networks among heterosexual PWID. It is also possible that IDU is under‐reported in this population, due to stigma associated with it [26](#jia225222-bib-0026){ref-type="ref"}, [76](#jia225222-bib-0076){ref-type="ref"}, [77](#jia225222-bib-0077){ref-type="ref"}, particularly in healthcare settings such as where these studies were recruited from.

The diagnosis of acute HCV infection has recently increased among HIV‐negative GBM [78](#jia225222-bib-0078){ref-type="ref"}, [79](#jia225222-bib-0079){ref-type="ref"}, [80](#jia225222-bib-0080){ref-type="ref"}. While this may be driven by increased testing and heightened awareness of HCV infection risk among this population, it has raised concern that with increased uptake of pre‐exposure prophylaxis (PrEP) to prevent HIV infection [81](#jia225222-bib-0081){ref-type="ref"}, [82](#jia225222-bib-0082){ref-type="ref"}, HCV infections may continue to rise among HIV‐negative GBM. It is possible that real time detection of this type of phylogenetic signal could be useful as a trigger to implement more in depth public health monitoring and interventions, such as increasing awareness around risk of sexual transmission of HCV among GBM [83](#jia225222-bib-0083){ref-type="ref"}, [84](#jia225222-bib-0084){ref-type="ref"}, and tailoring education to individuals based on their HIV infection status [85](#jia225222-bib-0085){ref-type="ref"}. Phylogenetic analysis of HCV NS5B sequences from HIV‐negative GBM receiving PrEP in Amsterdam demonstrated GBM‐specific HCV clusters containing both HIV‐positive and HIV‐negative individuals [86](#jia225222-bib-0086){ref-type="ref"}. Interventions implemented because of real time detection of phylogenetic signals in HCV are being developed and evaluated in the Netherlands and the United States [87](#jia225222-bib-0087){ref-type="ref"}, and may be useful in Australia to reduce transmission of HCV and investigate HCV outbreaks.

The multi‐risk profile Class (3) "GBM with IDU & sexual risk behaviour" had a combination of HCV acquisition through both sexual and drug use, and reported high proportions of recent methamphetamine injection, indicating the overlapping concurrent transmission risks present. Membership in this group was not independently associated with phylogenetic clustering. This finding suggests that members were more likely to have acquired their infection from people who were not sampled in this study, and that these networks are both broader and have not been sampled densely in this study. Those not sampled in this study were people with chronic HCV infection, and potentially people who are less likely to attend tertiary clinics or hospitals where participants in these studies were recruited. People who may be less likely to attend such settings are marginalized people or those not engaged in the healthcare system, particularly PWID [88](#jia225222-bib-0088){ref-type="ref"}, [89](#jia225222-bib-0089){ref-type="ref"}. This highlights the need to provide HCV testing and treatment in non‐tertiary clinics and other places where the people who need to access these services are most likely to visit. This also suggests that different strategies to prevent and treat HCV infection among GBM who inject methamphetamine may be needed to reduce transmission of HCV infection in this group.

This study demonstrates that LCA can be extremely useful to identify critical differences in potential transmission risk between groups that remain otherwise hidden. The methods described here can be used to examine unmeasured subgroups of participants based on multiple indicators, rather than individual factors, and overcomes some of the difficulties with traditional epidemiological methods used to investigate risk factors. While the classes identified do not represent actual individuals in the population, the LCA provides a useful mechanism for representing the heterogeneity of factors across the population.

Limitations include limited sampling of extremely high‐risk populations, such as PWID, particularly those in prison or otherwise unengaged in tertiary care, and the exclusion of chronically infected individuals. The network through which HCV is transmitted among HIV‐positive GBM has been sampled densely, in comparison to the network through which HCV is transmitted among HIV‐negative PWID. This is likely to have influenced the high overall proportion of phylogenetic clustering observed in this study. There is also difficulty in distinguishing between sexual and IDU as the route of HCV infection acquisition among people who report both categories of risk factors. However, creating multi‐risk profiles as done in this analysis can help to overcome this issue. There were also sampling bias in the way people were recruited to these studies, as they were conducted in tertiary care settings, and without any network‐based or respondent‐driven recruitment. Sampling was also limited by geographical area, with only selected sites in a limited number of Australian and New Zealand cities recruiting subjects; therefore, this study is not a random sample of the eligible populations and contains some bias.

5. Conclusions {#jia225222-sec-0020}
==============

A high proportion of phylogenetic clustering observed among participants with HCV/HIV co‐infection suggests transmission of HCV may occur through highly connected networks of HIV‐positive GBM. Increased screening and rapid delivery of HCV DAA treatment as prevention among HIV‐positive GBM should be considered, as it may be effective to reduce transmission of HCV in this population. There may also be a role for real time monitoring of the phylogeny, to detect signals related to transmission "hot spots" and trigger implementation of public health interventions. Transmission of HCV and HIV can occur rapidly through injecting and sexual networks [90](#jia225222-bib-0090){ref-type="ref"}, [91](#jia225222-bib-0091){ref-type="ref"}, and outbreak investigation using phylogenetic clustering analyses could improve monitoring and detection of emerging epidemics. This study provides a foundation upon which transmission of HCV among people with recent infection can be evaluated in the future, particularly in the setting of implementation of treatment as prevention to eliminate HCV infection among particular populations.
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